Transcat (NASDAQ:TRNS) Upgraded at Oppenheimer

07 Nov 2026, 14:38 by Danessa Lincoln · The Markets Daily

Oppenheimer upgraded shares of Transcat (NASDAQ:TRNS – Free Report) from a market perform rating to an outperform rating in a report published on Wednesday morning, MarketBeat.com reports. They currently have $115.00 price target on the scientific and technical instruments company’s stock.

Other equities research analysts also recently issued research reports about the stock. CJS Securities started coverage on shares of Transcat in a report on Tuesday, October 27th. They issued an “outperform” rating and a $115.00 price objective for the company. Northland Securities upgraded shares of Transcat from a “market perform” rating to an “outperform” rating and set a $95.00 price target on the stock in a research report on Wednesday, October 21st. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Transcat in a report on Tuesday, August 25th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Transcat presently has an average rating of “Hold” and an average target price of $108.33.

View Our Latest Research Report on TRNS

Transcat Trading Up 1.1%

Shares of NASDAQ:TRNS opened at $101.51 on Wednesday. The company has a quick ratio of 2.11, a current ratio of 2.49 and a debt-to-equity ratio of 0.36. The firm has a market cap of $953.18 million, a price-to-earnings ratio of 211.48 and a beta of 0.61. The company’s fifty day simple moving average is $86.94 and its 200 day simple moving average is $82.43. Transcat has a 12 month low of $50.23 and a 12 month high of $110.47.

Transcat (NASDAQ:TRNS – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The scientific and technical instruments company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.19. The business had revenue of $97.09 million during the quarter, compared to analysts’ expectations of $92.46 million. Transcat had a return on equity of 5.56% and a net margin of 0.99%. As a group, research analysts forecast that Transcat will post 2.06 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jaime A. Irick bought 2,275 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The shares were purchased at an average price of $101.26 per share, for a total transaction of $230,366.50. Following the acquisition, the chief executive officer directly owned 2,275 shares of the company’s stock, valued at $230,366.50. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.80% of the company’s stock.

Hedge Funds Weigh In On Transcat

Institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its holdings in Transcat by 41.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 24,929 shares of the scientific and technical instruments company’s stock valued at $2,204,000 after buying an additional 7,348 shares in the last quarter. R Squared Ltd purchased a new position in Transcat in the 3rd quarter worth $274,000. Riverbridge Partners LLC increased its stake in Transcat by 8.4% during the 3rd quarter. Riverbridge Partners LLC now owns 219,452 shares of the scientific and technical instruments company’s stock worth $19,404,000 after buying an additional 17,063 shares in the last quarter. Summit Creek Advisors LLC raised its position in Transcat by 23.8% in the third quarter. Summit Creek Advisors LLC now owns 58,135 shares of the scientific and technical instruments company’s stock valued at $5,140,000 after purchasing an additional 11,165 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Transcat during the third quarter worth about $221,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Key Stories Impacting Transcat

Here are the key news stories impacting Transcat this week:

Positive Sentiment: Zacks upgraded Transcat to Rank #1 (Strong Buy), citing improving earnings prospects, and included TRNS on its Strong Buy momentum-stock list. Zacks Strong Buy upgrade
Positive Sentiment: Northland Securities raised its EPS forecasts across 2027–2031, including lifting its FY2027 estimate to $2.00 from $1.71 and its FY2031 estimate to $3.69 from $3.53. The revisions suggest stronger expected earnings growth. Northland estimate revisions
Positive Sentiment: Oppenheimer raised its rating on Transcat to Outperform, adding to the favorable analyst sentiment. Oppenheimer rating upgrade
Positive Sentiment: Recent coverage linked TRNS reaching a 52-week high to an earnings beat and improved outlook. The supplied background also reports quarterly EPS of $0.64 versus a $0.45 consensus estimate, with revenue above forecasts. Transcat 52-week high following earnings beat
Neutral Sentiment: Northland maintained an Outperform rating but set a $95 price target, below the $101.32 share price cited in the background; this may temper the impact of its higher earnings forecasts. Northland rating and target

Transcat Company Profile

(Get Free Report)

Transcat, Inc (NASDAQ: TRNS) provides calibration, compliance, and measurement services for organizations that rely on accurate test and measurement equipment. The company supports customers in regulated industries, including life sciences, aerospace and defense, energy, manufacturing, and other industrial markets.